^
    1d
    CYTOSHRINK: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Apr 2026 --> Jul 2026
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=280, Not yet recruiting, Qilu Hospital of Shandong University
    New trial • Real-world evidence
    |
    Qibeian (iparomlimab/tuvonralimab)
    2d
    SIAG-BTC: Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Yervoy (ipilimumab) • gemcitabine • Tyvyt (sintilimab) • albumin-bound paclitaxel
    2d
    A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=41, Active, not recruiting, Ravi Amaravadi, MD | Recruiting --> Active, not recruiting | N=94 --> 41 | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2027 --> Jul 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • hydroxychloroquine
    2d
    WITNESS: Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer (clinicaltrials.gov)
    P=N/A, N=623, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    XTX101-01: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Completed, Xilio Development, Inc. | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    Tecentriq (atezolizumab) • vilastobart (XTX101)
    3d
    A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases. (PubMed, Medicine (Baltimore))
    The ipilimumab-pembrolizumab combination demonstrated the highest reporting odds ratio (97.2, 95% CI: 58.1-162.4). Integration of pharmacovigilance and transcriptomic data implicates coordinated effects of melanocyte-lineage antigens, innate immune and mitochondrial function pathways in vitiligo pathogenesis. This study aimed to systematically characterize the risk profile, onset timing, and potential biological mechanisms of ICI-induced vitiligo across different treatment strategies and cancer types.
    Retrospective data • Journal • Checkpoint inhibition • Real-world evidence
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab)
    3d
    Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial (clinicaltrials.gov)
    P2, N=134, Not yet recruiting, Obstetrics & Gynecology Hospital of Fudan University
    New P2 trial
    |
    Kaitanni (cadonilimab)
    3d
    QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fujian Medical University
    New P2 trial
    |
    Avastin (bevacizumab) • Qibeian (iparomlimab/tuvonralimab)
    4d
    Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. (PubMed, Cancer Immunol Immunother)
    In this large real-world cohort, first-line NIVO + IPI therapy demonstrated meaningful clinical activity and an acceptable safety profile in advanced ESCC. Treatment outcomes varied according to metastatic patterns, suggesting an influence of organ-specific immune microenvironments, and CAR emerged as a simple and robust prognostic biomarker. These findings support the real-world applicability of dual immune checkpoint blockade and highlight the importance of host immune context in patient selection.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    5d
    A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2 (2025-521608-23-00)
    P1/2, N=56, Not yet recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale
    New P1/2 trial
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Imjudo (tremelimumab-actl)
    6d
    QUARTZ-CC: Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=103, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)